The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.
The user is struggling with hair loss despite using finasteride, minoxidil, and ketoconazole, and addressing vitamin D and ferritin deficiencies. They experienced a temporary improvement but are now shedding hair again and feeling stressed.
The user is frustrated with Koshinemall's disorganized service and delayed shipping of KX-826. They are seeking feedback on whether others have received their KX-826 orders.
The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.
A 29-year-old woman is experiencing gradual hair thinning since age 15, suspects Androgenic Alopecia, and has tried 5% minoxidil with little success. She has purchased various hair loss treatments including minoxidil, dutasteride, finasteride, and spironolactone, but is cautious about starting them due to potential interactions with her ADHD medication.
The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
Increased scalp itching during shedding phases while on finasteride treatment may coincide with hair regrowth and recovery. This suggests that itching might not always indicate continued hair loss and could encourage persistence with the treatment.
The user experienced bladder and prostate discomfort after taking finasteride and stopped the medication, but symptoms returned upon resuming at a lower dose. The doctor suggested trying dutasteride as an alternative.
The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.
The conversation discusses hair loss concerns, specifically traction alopecia and hair loss from acne. It mentions that sleeping on one side is unlikely to cause traction alopecia.
The user is experiencing shedding of thick, healthy hair after using KX826 0.5% for a month. They are concerned about losing coverage and are seeking others' experiences with regrowth.
Topical aldactone is discussed for its effects on men's hair and muscles. The conversation explores its potential benefits and side effects compared to other treatments like Minoxidil, finasteride, and RU58841.
The user is using dutasteride, oral minoxidil, and ketoconazole shampoo for hair loss but still experiences hair shedding. Despite using these treatments for about 1.5 years, the user jokes about the ineffectiveness and dandruff issues.
Oral minoxidil at 0.625mg/day caused dizziness, heart thumping, and fatigue. The user is concerned if these side effects will subside or indicate unsuitability for the medication.
People who had posted about using pyrilutamide for hair loss, but did not return with an update; the potential side effects of pyrilutamide, RU58841 and other treatments such as minoxidil and finasteride were discussed.
The user has been using finasteride, minoxidil, and Nizoral for 9 months with little progress in hair regrowth and is considering switching to dutasteride. They experience daily scalp pain and anxiety, and are exploring other treatments like Head & Shoulders and consulting a dermatologist.
Ashwagandha topical formulation may increase hair density and reduce hair loss, but results seem too good to be true due to a small sample size. Users are skeptical about its effectiveness and are experimenting with different application methods.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
The user is experiencing a second hair shedding phase and increased flaking and itching while using minoxidil 5% nightly and microneedling every two weeks, with needle length increasing over time. Other users suggest the hair loss may continue without the use of finasteride.
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.